Lupus erythematosus - Lupus Érythematosus
☆ AI Dermatology — Free Service
Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Dina hasil Stiftung Warentest 2022 ti Jerman, kapuasan konsumen sareng ModelDerm ngan ukur langkung handap tibatan konsultasi telemedicine anu mayar.
Nembongan salaku erythema nu rada ungu‑ungu.
Ruam kukupu nu ilaharna muncul dina beungeut.
relevance score : -100.0%
ReferencesNgidentipikasi jeung ngagolongkeun cutaneous lupus erythematosus (CLE) nyababkeun tantangan diagnostik, sabab kudu dibédakeun ti systemic lupus erythematosus anu ogé ngalibetkeun kulit. Panaliti panganyarna ngajelaskeun faktor genetik, lingkungan, jeung imunologis anu peran dina CLE. Paparan narkoba sacara khusus muncul salaku salah sahiji pemicu utama CLE. Pangobatan ngalibatkeun terapi topikal jeung sistemik, kalebet biologik anu ngajangjikeun (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059), kalayan efektivitasna geus dibuktikeun dina uji klinis.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) nyertakeun rupa‑rupa masalah kulit, sababaraha diantarana tiasa patali jeung masalah kaséhatan anu leuwih lega. Éta dikategorikeun kana sababaraha jinis, sapertos acute CLE (ACLE), sub‑acute CLE (SCLE), jeung chronic CLE (CCLE). CCLE ngawengku discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus, jeung lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus mangrupikeun sakelompok panyakit otoimun anu tiasa mangaruhan sababaraha bagian awak. Sababaraha jinis, sapertos systemic lupus erythematosus (SLE), mangaruhan sababaraha organ, sedengkeun anu sanésna, sapertos cutaneous lupus erythematosus (CLE), utamina mangaruhan kulit. Kami ngagolongkeun sababaraha jinis CLE dumasar kana campuran tanda klinis, pamariksaan jaringan, sareng tes getih, tapi aya seueur variasi antara individu. Masalah kulit sering muncul kusabab faktor sapertos paparan sinar panonpoé, ngaroko, atawa pangobatan anu tangtu.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Pangna lupus érythematosus (Lupus erythematosus) teu jelas. Dina kembar idéntik, lamun salah sahiji kapangaruhan, aya 24 % kamungkinan nu séjén ogé bakal kapangaruhan. Hormon séks awéwé, paparan sinar panonpoé, ngaroko, kakurangan vitamin D, jeung sababaraha inféksi ogé dipercaya ningkatkeun résiko.
Pangobatan bisa ngawengku NSAID, kortikosteroid, immunosuppressants, hydroxychloroquine, jeung methotrexate. Sanajan kortikosteroid efektif, pamakéan jangka panjangna tiasa nyababkeun efek samping.